{"version":"company-facts.v1","source":"https://secwatch.observer","generated_at":"2026-06-04T13:59:41.648347+00:00","company":{"ticker":"SIGY","cik":1642159,"company_name":"Sigyn Therapeutics, Inc."},"pagination":{"limit":100,"returned":7,"next_cursor":null},"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer","facts":[{"fact_type":"material_agreement","fact_key":"a3a2aa68acf2db23ef9f4226e3a6f6e8ec0312c5","cik":1642159,"ticker":"SIGY","company_name":"Sigyn Therapeutics, Inc.","filed_at":"2026-02-20T23:59:59+00:00","payload":{"action":"entry","agreement_name":"Convertible Note Purchase Agreement","agreement_type":"equity_purchase","counterparty":"Lambda Venture Partners, LLC","effective_date":"2026-02-06","item_codes_triggered":["1.01"],"value_text":"$27,777.77"},"claim":"Sigyn Therapeutics, Inc. entered into Convertible Note Purchase Agreement with Lambda Venture Partners, LLC valued at $27,777.77 (effective 2026-02-06).","evidence_excerpt":"On February 6, 2026, Sigyn Therapeutics, Inc. (the “Company”) entered into a one-year Convertible Note Purchase Agreement (the “Purchase Agreement”) with Lambda Venture Partners, LLC, in the principal amount of $27,777.77","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001493152-26-007574","anchor_url":"https://secwatch.observer/filing/0001493152-26-007574#claim-a3a2aa68acf2db23ef9f4226e3a6f6e8ec0312c5","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1642159/000149315226007574/0001493152-26-007574-index.htm"},{"fact_type":"material_agreement","fact_key":"2823a345373d60760d5c434619de06648648103e","cik":1642159,"ticker":"SIGY","company_name":"Sigyn Therapeutics, Inc.","filed_at":"2026-02-20T23:59:59+00:00","payload":{"action":"entry","agreement_name":"Convertible Note Purchase Agreement","agreement_type":"equity_purchase","counterparty":"Osher Capital Partners, LLC","effective_date":"2026-02-12","item_codes_triggered":["1.01"],"value_text":"$22,222.22"},"claim":"Sigyn Therapeutics, Inc. entered into Convertible Note Purchase Agreement with Osher Capital Partners, LLC valued at $22,222.22 (effective 2026-02-12).","evidence_excerpt":"On February 12, 2026, Sigyn Therapeutics, Inc. (the “Company”) entered into a one-year Convertible Note Purchase Agreement (the “Purchase Agreement”) with Osher Capital Partners, LLC, in the principal amount of $22,222.22","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001493152-26-007574","anchor_url":"https://secwatch.observer/filing/0001493152-26-007574#claim-2823a345373d60760d5c434619de06648648103e","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1642159/000149315226007574/0001493152-26-007574-index.htm"},{"fact_type":"material_agreement","fact_key":"8c6ab812e7a86a1f55580279397cf1858b486c77","cik":1642159,"ticker":"SIGY","company_name":"Sigyn Therapeutics, Inc.","filed_at":"2026-02-20T23:59:59+00:00","payload":{"action":"entry","agreement_name":"Convertible Note Purchase Agreement","agreement_type":"equity_purchase","counterparty":"Brio Capital Master Fund, Ltd","effective_date":"2026-02-12","item_codes_triggered":["1.01"],"value_text":"$22,222.22"},"claim":"Sigyn Therapeutics, Inc. entered into Convertible Note Purchase Agreement with Brio Capital Master Fund, Ltd valued at $22,222.22 (effective 2026-02-12).","evidence_excerpt":"On February 12, 2026, Sigyn Therapeutics, Inc. (the “Company”) entered into a one-year Convertible Note Purchase Agreement (the “Purchase Agreement”) with Brio Capital Master Fund, Ltd, in the principal amount of $22,222.22","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001493152-26-007574","anchor_url":"https://secwatch.observer/filing/0001493152-26-007574#claim-8c6ab812e7a86a1f55580279397cf1858b486c77","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1642159/000149315226007574/0001493152-26-007574-index.htm"},{"fact_type":"executive_change","fact_key":"39e757b58f","cik":1642159,"ticker":"SIGY","company_name":"Sigyn Therapeutics, Inc.","filed_at":"2025-03-07T23:59:59+00:00","payload":{"action":"appointed","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2025-02-26","interim":true,"role":"interim Chief Financial Officer","role_category":"cfo","successor_name":null,"successor_named":false},"claim":"James Joyce was appointed as interim Chief Financial Officer at Sigyn Therapeutics, Inc..","evidence_excerpt":"Mr. James Joyce, our Chief Executive Officer, will serve as our interim Chief Financial Officer.","confidence":1.0,"filing_url":"https://secwatch.observer/filing/0001493152-25-009462","anchor_url":"https://secwatch.observer/filing/0001493152-25-009462#claim-39e757b58f","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1642159/000149315225009462/0001493152-25-009462-index.htm"},{"fact_type":"executive_change","fact_key":"a45e266906","cik":1642159,"ticker":"SIGY","company_name":"Sigyn Therapeutics, Inc.","filed_at":"2025-03-07T23:59:59+00:00","payload":{"action":"retired","action_category":"departure","departure_tone":"routine","effective_date":"2025-02-26","interim":false,"role":"Chief Financial Officer","role_category":"cfo","successor_name":"James Joyce","successor_named":true},"claim":"Gerald DeCiccio retired as Chief Financial Officer at Sigyn Therapeutics, Inc..","evidence_excerpt":"On February 26, 2025, our Chief Financial Officer, Mr. Gerald DeCiccio provided us a notice of retirement, effective immediately.","confidence":1.0,"filing_url":"https://secwatch.observer/filing/0001493152-25-009462","anchor_url":"https://secwatch.observer/filing/0001493152-25-009462#claim-a45e266906","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1642159/000149315225009462/0001493152-25-009462-index.htm"},{"fact_type":"executive_change","fact_key":"11895cb13f","cik":1642159,"ticker":"SIGY","company_name":"Sigyn Therapeutics, Inc.","filed_at":"2025-01-16T23:59:59+00:00","payload":{"action":"appointed","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2025-01-11","interim":false,"role":"Director","role_category":"director","successor_name":null,"successor_named":false},"claim":"Michael Ryan was appointed as Director at Sigyn Therapeutics, Inc..","evidence_excerpt":"On January 11, 2025, our Board of Directors appointed Michael Ryan to our Board of Directors.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001493152-25-002575","anchor_url":"https://secwatch.observer/filing/0001493152-25-002575#claim-11895cb13f","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1642159/000149315225002575/0001493152-25-002575-index.htm"},{"fact_type":"material_agreement","fact_key":"66362895f0c4bd4c9c6a414064f12776e76df26c","cik":1642159,"ticker":"SIGY","company_name":"Sigyn Therapeutics, Inc.","filed_at":"2024-04-16T23:59:59+00:00","payload":{"action":"amendment","agreement_name":"Debentures","agreement_type":"notes_offering","counterparty":"Brio Capital Master Fund Ltd. and Osher Capital Partners, LLC","effective_date":"2024-04-10","item_codes_triggered":["1.01"],"value_text":"$110,000 and $275,000"},"claim":"Sigyn Therapeutics, Inc. amended Debentures with Brio Capital Master Fund Ltd. and Osher Capital Partners, LLC valued at $110,000 and $275,000 (effective 2024-04-10).","evidence_excerpt":"Brio and Osher agreed to amend an additional $110,000 and $275,000, respectively, of Debentures to extend the maturity dates of such Debentures to March 31, 2025 in return for an increase in principal amount of such Debentures to $125,000 and $316,350","confidence":0.7,"filing_url":"https://secwatch.observer/filing/0001493152-24-014866","anchor_url":"https://secwatch.observer/filing/0001493152-24-014866#claim-66362895f0c4bd4c9c6a414064f12776e76df26c","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1642159/000149315224014866/0001493152-24-014866-index.htm"}]}